Myeloma Trial, Recruiting (NCT00935090)

Myeloma Trial, Recruiting NCT00935090 Sponsor: Barbara Ann Karmanos Cancer Institute Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT00935090 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a solid tumour or blood cancer confirmed through a tissue sample (biopsy)
People who are waiting for a biopsy or surgery to investigate a lump or mass that was found during an examination or routine scan
People who are able to lie still inside a PET scanner (a type of medical imaging machine)
People whose body size and weight are suitable to fit inside the scanning machine
People who are not pregnant or breastfeeding, with a negative pregnancy test result confirmed
People who are able to become pregnant or father a child and are using an effective form of contraception

Who may not be able to join:

People who are pregnant or currently breastfeeding
People whose body size or weight is not compatible with the scanning equipment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00935090

Sponsor: Barbara Ann Karmanos Cancer Institute

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

More information: https://clinicaltrials.gov/study/NCT00935090

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a solid tumour or blood cancer confirmed through a tissue sample (biopsy)
People who are waiting for a biopsy or surgery to investigate a lump or mass that was found during an examination or routine scan
People who are able to lie still inside a PET scanner (a type of medical imaging machine)
People whose body size and weight are suitable to fit inside the scanning machine
People who are not pregnant or breastfeeding, with a negative pregnancy test result confirmed
People who are able to become pregnant or father a child and are using an effective form of contraception

Who may not be able to join:

People who are pregnant or currently breastfeeding
People whose body size or weight is not compatible with the scanning equipment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Barbara Ann Karmanos Cancer Institute

Registry

ClinicalTrials.gov

Start date

1 September 2009

Est. completion

1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs; Changes in thymidine kinase, thymidylate synthase, and standardized uptake values

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov